Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Delineation of phenotypes and genotypes related to cohesin structural protein RAD21.

Krab LC, Marcos-Alcalde I, Assaf M, Balasubramanian M, Andersen JB, Bisgaard AM, Fitzpatrick DR, Gudmundsson S, Huisman SA, Kalayci T, Maas SM, Martinez F, McKee S, Menke LA, Mulder PA, Murch OD, Parker M, Pie J, Ramos FJ, Rieubland C, Rosenfeld Mokry JA, Scarano E, Shinawi M, Gómez-Puertas P, Tümer Z, Hennekam RC.

Hum Genet. 2020 Mar 19. doi: 10.1007/s00439-020-02138-2. [Epub ahead of print]

PMID:
32193685
2.

Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders.

Ottenhoff MJ, Krab LC, Elgersma Y.

eNeuro. 2020 Mar 6;7(2). pii: ENEURO.0392-19.2020. doi: 10.1523/ENEURO.0392-19.2020. Print 2020 Mar/Apr. No abstract available.

3.

Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1.

Rietman AB, van der Vaart T, Plasschaert E, Nicholson BA, Oostenbrink R, Krab LC, Descheemaeker MJ, Wit MY, Moll HA, Legius E, Nijs PFA.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):319-328. doi: 10.1002/ajmg.b.32612. Epub 2017 Dec 15.

PMID:
29243874
4.

Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome.

van Beveren NJ, Krab LC, Swagemakers S, Buitendijk GH, Boot E, van der Spek P, Elgersma Y, van Amelsvoort TA.

PLoS One. 2012;7(3):e33473. doi: 10.1371/journal.pone.0033473. Epub 2012 Mar 22. Erratum in: PLoS One. 2012;7(4): doi/10.1371/annotation/d80f4e7d-5e96-41da-9dae-717b0d0d3c60. Buitendijk, Gabriella [corrected to Buitendijk, Gabriëlle H S]..

5.

Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients.

van Beveren NJ, Buitendijk GH, Swagemakers S, Krab LC, Röder C, de Haan L, van der Spek P, Elgersma Y.

PLoS One. 2012;7(2):e32618. doi: 10.1371/journal.pone.0032618. Epub 2012 Feb 29.

6.

Motor learning in children with neurofibromatosis type I.

Krab LC, de Goede-Bolder A, Aarsen FK, Moll HA, De Zeeuw CI, Elgersma Y, van der Geest JN.

Cerebellum. 2011 Mar;10(1):14-21. doi: 10.1007/s12311-010-0217-2.

7.

Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior.

Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA.

J Pediatr. 2009 Mar;154(3):420-5, 425.e1. doi: 10.1016/j.jpeds.2008.08.045. Epub 2008 Oct 31.

PMID:
18950800
8.

Impact of neurofibromatosis type 1 on school performance.

Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, Moll HA, Elgersma Y.

J Child Neurol. 2008 Sep;23(9):1002-10. doi: 10.1177/0883073808316366.

PMID:
18827266
9.

Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.

Krab LC, Goorden SM, Elgersma Y.

Trends Genet. 2008 Oct;24(10):498-510. doi: 10.1016/j.tig.2008.07.005. Epub 2008 Sep 4. Review.

PMID:
18774199
10.

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.

Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, Silva AJ, de Zeeuw CI, Moll HA, Elgersma Y.

JAMA. 2008 Jul 16;300(3):287-94. doi: 10.1001/jama.300.3.287.

11.

Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging.

van Engelen SJ, Krab LC, Moll HA, de Goede-Bolder A, Pluijm SM, Catsman-Berrevoets CE, Elgersma Y, Lequin MH.

AJNR Am J Neuroradiol. 2008 Apr;29(4):816-22. doi: 10.3174/ajnr.A0921. Epub 2008 Mar 13.

Supplemental Content

Support Center